UCB’s Acquisition Of New Life Sciences Campus

Addleshaw Goddard advised UCB.

The agreement to purchase the new campus in Windlesham, Surrey by UCB demonstrates the global biopharmaceutical company’s commitment to the UK’s life sciences sector and its drive to support cutting-edge research and development, as well as develop innovative treatments for patients with neurological and immunological conditions.

The acquisition of the 47-acre site, from Eli Lilly and Company Limited, due to complete in November 2020, will undergo a significant modernisation, prior to UCB relocating from its current UK headquarters in Slough, Berkshire. The relocation to a state-of-the-art facility will underpin UCB’s promise to invest more than £1 billion over five years and support more than 650 high-value jobs as well as support its wider collaborations with UK universities, charities and other companies.

The Addleshaw Goddard team was led by partner Chris Cartwright (Picture), with support from managing associates Elly Chatfield and Jamie Lee Harris (Real Estate), partners Gary Sector (Planning), Michelle Headrige (Environment), and partner Andy McVeigh, Sam Comer and Rob Easton (Construction) and Justine Delroy and Chris Connors (Tax).

Involved fees earner: Christopher Cartwright – Addleshaw Goddard; Elly Chatfield – Addleshaw Goddard; Sam Comer – Addleshaw Goddard; Chris Connors – Addleshaw Goddard; Justine Delroy – Addleshaw Goddard; Rob Easton – Addleshaw Goddard; Michelle Headrige – Addleshaw Goddard; Andy McVeigh – Addleshaw Goddard; Gary Sector – Addleshaw Goddard;

Law Firms: Addleshaw Goddard;

Clients: UCB S.A.;

Print Friendly, PDF & Email